Crexont prescriptions reached 964 per week by mid-February, capturing 15% of Rytary’s volume and exceeding market expectations. JP Morgan upgraded Amneal to Overweight, raising its price target ...

Amneal Pharmaceuticals, Inc. offers strong growth prospects with undervalued stock, rising revenues, reduced debt, and key ...

BRIDGEWATER, N.J., January 29, 2025--Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025 BRIDGEWATER, N.J., January 23, 2025--Amneal ...

Amneal Pharmaceuticals (AMRX) shares rallied 6% in the last trading session to close at $8.30. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

Chirag Patel, Co-CEO, highlighted Amneal's "stellar financial performance" in 2024, citing double-digit revenue and adjusted EBITDA growth, reduction of net leverage below four times, and notable ...

Amneal Pharmaceuticals (NYSE:NASDAQ:AMRX), a commercial-stage biopharmaceutical company with a market capitalization of $2.74 billion, has been making significant strides in the pharmaceutical ...

Amneal Pharma ((AMRX)) has held its Q4 earnings call. Read on for the main highlights of the call. See what stocks are receiving Strong Buy ratings from top-rated analysts. Filter, analyze, and ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the fourth quarter and full year ended December ...

BRIDGEWATER, N.J., January 29, 2025--Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025 BRIDGEWATER, N.J., January 23, 2025--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ...